WGS
GeneDx Holdings Corp.
$61.69
-4.45 (-6.73%)
At close · Jul 16
Market Cap
$1.83B
Shares
29,688,027
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$427.54M
+40%
FY2025
Net Income
-$21.02M
+59.8%
FY2025
Gross Margin
69.74%
+6.1pp
FY2025
Operating Margin
-3.06%
+4.5pp
FY2025
Diluted EPS
-$0.73
+62.4%
FY2025
Operating Cash Flow
$33.28M
+216.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| $475M – $490M | $442.68M | $427.54MG | $305.45M | $202.57M | $234.69M | $212.2M | — | |
| — | — | — | — | $1.11M | — | — | — | |
| — | $134.77M | $129.37M | $111.05M | $112.56M | $261.44M | $228.8M | — | |
| — | $307.91M | $298.17M | $194.4M | $90.01M | -$26.75M | -$16.6M | — | |
| — | — | 69.74% | 63.64% | 44.43% | -11.4% | -7.82% | — | |
| — | $79.25M | $72.03M | $45.72M | $58.27M | $86.2M | $105.16M | — | |
| — | — | $88.41M | $67.37M | $60.96M | $134.91M | $112.74M | — | |
| — | — | $150.82M | $101.11M | $133.76M | $203.33M | $205.99M | $206.2K | |
| — | $10.1M | $9.6M | $7.9M | $19.7M | $59.31M | $21.81M | — | |
| — | — | — | $1.75M | $6.53M | $24.16M | — | — | |
| — | -$66M | -$13.08M | -$23.21M | -$180.6M | -$667.65M | -$446.15M | -$206.2K | |
| — | — | -3.06% | -7.6% | -89.15% | -284.48% | -210.25% | — | |
| — | -$55.9M | -$3.48M | -$15.31M | -$160.9M | -$608.34M | -$424.34M | — | |
| — | $3M | — | — | — | $3.21M | $2.84M | — | |
| — | $4.56M | — | — | — | $2.54M | $79K | $13.95K | |
| — | -$11.48M | -$8.06M | -$29.42M | $3.9M | $69.62M | $200.76M | — | |
| — | -$77.47M | -$21.14M | -$52.63M | -$176.69M | -$598.03M | -$245.39M | -$39.91M | |
| — | $334K | -$116K | -$343K | -$926K | -$49.05M | $0 | — | |
| — | -$77.81M | -$21.02M | -$52.29M | -$175.77M | -$548.98M | -$245.39M | -$39.91M | |
| — | — | -4.92% | -17.12% | -86.77% | -233.91% | -115.64% | — | |
| — | — | — | — | — | — | -$245.39M | — | |
| — | -$78.03M | -$20.92M | -$51.88M | -$175.34M | -$548.98M | -$245.39M | — | |
| USD/shares | — | — | -$0.73 | -$1.94 | -$7.23 | -$53.79 | -$74.91 | — |
| USD/shares | — | — | -$0.73 | -$1.94 | -$7.23 | -$53.79 | -$74.91 | — |
| shares | — | — | 28.64M | 26.89M | 24.31M | 10.24M | 3.28M | — |
| shares | — | — | 28.64M | 26.89M | 24.31M | 10.24M | 3.28M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
4.14×
Diagnostics & Research median 2.95×
EV/EBIT
—
Diagnostics & Research median 31.75×
P/E (TTM)
—
Diagnostics & Research median 32.60×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| GeneDx | $423,088,000 | $302,293,000 | $194,376,000 | $122,234,000 |
| All Other Segments | $4,451,000 | $3,157,000 | $8,190,000 | — |
| Legacy Sema4 | — | — | $8,190,000 | $112,460,000 |
| Other | — | $3,157,000 | $8,190,000 | — |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| Diagnostic Test | $416,668,000 | $302,157,000 | $195,654,000 | $227,334,000 | $205,100,000 | $175,351,000 | — |
| Diagnostic Test Third Party Insurance | $345,235,000 | $234,699,000 | $134,491,000 | $173,624,000 | $169,576,000 | $138,153,000 | — |
| Diagnostic Test Institutional Customers | $70,072,000 | $65,115,000 | $59,497,000 | $46,124,000 | $31,717,000 | $35,200,000 | — |
| Product And Service Other | $10,871,000 | $3,293,000 | $6,912,000 | $7,360,000 | $7,095,000 | $3,971,000 | $4,507,000 |
| Diagnostic Test Self Pay | $1,361,000 | $2,343,000 | $1,666,000 | $7,586,000 | $3,807,000 | $1,998,000 | — |
| Diagnostic Test Institutional Customers | — | — | — | — | $31,717,000 | $35,200,000 | $20,888,000 |
| Diagnostic Test | — | — | — | — | $205,100,000 | $175,351,000 | $191,667,000 |
| Diagnostic Test Self Pay | — | — | — | — | $3,807,000 | $1,998,000 | $1,241,000 |
| Diagnostic Test Third Party Insurance | — | — | — | — | $169,576,000 | $138,153,000 | $169,538,000 |
Key facts
CIK
1818331
CUSIP
81663L200
13F (30d)
15 filings
15 filers
Visit website
Investor relations